Daphne Zohar gathers a blue-ribbon panel of dealmakers for BioPharm America in Boston to focus on unexpected dynamics that can derail high profile transactions. In this interview, she provides fresh perspectives that challenge conventional views of partnering and describes the trail-blazing strategy of her firm, PureTech Ventures. Read more »
Ahead of BioPharm America 2010 in Boston, Nycomed’s lead dealmaker, Kerstin Valinder, offers an in-depth discussion of partnering that jumps to the top of our ‘Summer Reading’ list. In this exclusive interview with partneringNEWS she traces the company’s spectacular growth to EUR 3 billion in sales, outlines Nycomed’s targets for further growth, and shares fresh views on how the ‘professionalization’ of partnering changes business development. Read more »
“We see partnering as an integral part of building the business for the long term, and you can think of our business development efforts for partnering as building an external R&D engine,” said Anna Protopapas. Read more »
Supported by fresh research and backed by newly constructed, cutting edge manufacturing facilities, Immudyne is re-introducing European partners to the benefits of beta glucan at BIO-Europe Spring® 2010. Read more »
Meetings in Barcelona with pharmaceuticals and biotechs represent the first business development effort outside Japan for Chiome Bioscience, which recently established a successful record for generating antibodies with unique function against multiple-trans-membrane proteins through a proprietary in vitro platform called the ADLib system. Read more »
Cevec Pharmaceuticals uniquely offers a single human cell line from original research all the way to market-scale production with CAP-T, a transient cell line for rapid protein expression in drug discovery and development as a complement to the Cevec amniocyte high yield production (CAP) technology. Read more »
Oncolix thinks its first-in-class drug Prolanta has the makings to become a blockbuster drug for breast cancer therapy. Read more »
One week ahead of BIO-Europe 2009, Medgenics announced its first preclinical development and option agreement with what it described as “a major international biopharmaceutical company that is a market leader in the field of hemophilia.” Read more »
Newsletter